NCOA3 and plasma cell myeloma: In addition, NSD2-induced stabilization of steroid receptor coactivator 3 (SRC3) is involved in resistance to bortezomib, a proteasomal inhibitor used in multiple myeloma therapy, while disrupting the interaction between NSD2 and SRC3 recovers the sensitivity to bortezomib [157].